Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Paraganglioma × Sunitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Carcinoma, Renal Cell 63 Neoplasm Metastasis 23 Kidney Neoplasms 23 Breast Neoplasms 14 Neoplasms 13 Prostatic Neoplasms 12 Urinary Bladder Neoplasms 9 Melanoma 8 Glioblastoma 8 Gastrointestinal Stromal Tumors 8 Sarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 6 Ovarian Neoplasms 5 Liver Neoplasms 5 Esophageal Neoplasms 5 Colorectal Neoplasms 5 Thyroid Neoplasms 4 Solid Tumors 4 Recurrence 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Carcinoma, Hepatocellular 4 Adenocarcinoma 4 Uveal Melanoma 3 Thymoma 3 Stomach Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

lutetium Lu 177 dotatate 4 3-Iodobenzylguanidine 3 gallium Ga 68 dotatate 2 anlotinib 2 Phenoxybenzamine 2 Magnetic Resonance Spectroscopy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 olaparib 1 lanreotide 1 fluorodopa F 18 1 fludarabine phosphate 1 cabozantinib 1 belzutifan 1 atezolizumab 1 Vorinostat 1 Temozolomide 1 Sunitinib 1 Specimen Handling 1 Radiosurgery 1 Interleukin-13 1 Genetic Testing 1 Fluorodeoxyglucose F18 1 Doxazosin 1 Cyclophosphamide 1 Blood Specimen Collection 1 Biopsy 1 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 1 3-fluorobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01371201 2022-08-04

FIRSTMAPPP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡